Could delaying radiation be just as good for advanced nasopharyngeal cancer?
NCT ID NCT07235319
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 3 trial is testing whether giving radiation only when needed (salvage therapy) works as well as giving it right away after immunotherapy and chemotherapy in people with nasopharyngeal cancer that has spread. The goal is to see if delaying radiation can reduce side effects without hurting survival. About 260 adults with newly diagnosed metastatic disease will take part.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
PD-1 inhibitor (toripalimab, tislelizumab, or camrelizumab) plus chemotherapy (cisplatin) and locoregional radiotherapy
What this could lead to
If successful, this could show that delaying radiotherapy until needed is as effective as immediate treatment, potentially reducing side effects for patients with metastatic nasopharyngeal cancer.
What could go wrong
This is a non-inferiority trial, so it may only confirm that the delayed approach is not worse, not necessarily better. The study is still recruiting and results are years away.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NASOPHARANGEAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fujian Cancer Hospital
NOT_YET_RECRUITINGFuzhou, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Guangxi Medical University Cancer Hospital
NOT_YET_RECRUITINGNanning, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hunan Cancer Hospital
NOT_YET_RECRUITINGChangsha, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, 510060, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Zhejiang Cancer Hospital
NOT_YET_RECRUITINGHangzhou, China
Contact Phone: •••-•••-•••• Email: •••••@•••••